-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

634.O3.6 634. Myeloproliferative Syndromes: Clinical: Combination Therapy in MPN

Myeloproliferative Syndromes: Clinical Program: Oral and Poster Abstracts
Type: Oral
Monday, December 7, 2015: 4:30 PM-6:00 PM
W315, Level 3 (Orange County Convention Center)
Moderators:
Alison Moliterno, MD, Johns Hopkins University School of Medicine and Laura C. Michaelis, MD, Medical College of Wisconsin

Disclosures:
Michaelis: Incyte: Membership on an entity’s Board of Directors or advisory committees ; CTI Biopharma: Membership on an entity’s Board of Directors or advisory committees ; Wyeth: Membership on an entity’s Board of Directors or advisory committees ; Pfizer: Equity Ownership .
4:30 PM

Naval Daver, MD1, Guillermo Garcia-Manero, MD2, Jorge E. Cortes, MD3, Lingsha Zhou4*, Sherry Pierce, BSN, BA3*, Naveen Pemmaraju, MD3, Elias Jabbour3, Courtney DiNardo, MD3, Tapan Kadia, MD3, Gautam Borthakur, MD3, Farhad Ravandi, MD3, Marina Konopleva, MD, PhD5, Franklin Wynn6*, Stephanie Van Derbur6*, Zeev Estrov, MD3, Hagop M. Kantarjian, MD3 and Srdan Verstovsek, MD3

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, Houston, TX
2Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX
5Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
6The University of Texas M. D. Anderson Cancer Center, Houston, TX

4:45 PM

Stine Ulrik Mikkelsen, MD1*, Lasse Kjær, MSc, PhD1*, Vibe Skov, MSc, PhD1*, Mads Emil Bjørn, MD, PhD Student1*, Christen Lykkegaard Andersen, MD, PhD2*, Ole Weis Bjerrum, MD, DMSc2*, Nana Brochmann, MD, PhD Student1*, Daniel El Fassi, MD, PhD3*, Torben A Kruse, Professor, PhD4*, Thomas Stauffer Larsen, MD, PhD5*, Torben Mourits-Andersen, MD6*, Claus Henrik Nielsen, MD, Professor, DMSc7*, Niels Pallisgaard, MSc8*, Mads Thomassen, MSc, PhD4* and Hans Carl Hasselbalch, MD, Professor, DMSc1

1Department of Hematology, Roskilde University Hospital, Roskilde, Denmark
2Department of Hematology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark
3Department of Hematology, Herlev University Hospital, Copenhagen, Denmark
4Department of Clinical Genetics, Odense University Hospital, Odense C, Denmark
5Department of Hematology, Odense University Hospital, Odense, Denmark
6Department of Hematology, Sydvestjysk Hospital, Esbjerg, Denmark
7Institute for Inflammation Research, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark
8Department of Pathology, Roskilde University Hospital, Roskilde, Denmark

5:00 PM

Vikas Gupta, MD, FRCP, FRCPath1, Claire N. Harrison2, Hans Hasselbalch, MD3, Lisa Pieri, MD, PhD4*, Steffen Koschmieder, MD5, Francisco Cervantes6, Weichao Bao, PhD7*, Stacey Kalambakas, MD7*, Edric Atienza, MSHS7*, Prashanth Gopalakrishna, MBBS, MRCS8* and Florian H. Heidel, MD9

1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
2Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
3Department of Hematology, Roskilde University Hospital, Roskilde, Denmark
4Azienda Ospedaliera-Universitaria Careggi, University of Florence, Florence, Italy
5RWTH Aachen University Hospital, Aachen, Germany
6Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
7Novartis Pharmaceuticals Corporation, East Hanover, NJ
8Novartis Pharma AG, Basel, Switzerland
9Otto-von-Guericke-University Magdeburg, Magdeburg, Germany

5:15 PM

Frank Stegelmann, MD1*, Markus Bangerter, MD2*, Florian H Heidel, MD3, Martin Griesshammer, MD4*, Holger Hebart, MD5, Andreas Hochhaus, MD6, Steffen Koschmieder, MD7, Robert Möhle, MD8, Andreas Reiter, MD9*, Christof Scheid10, Rebecca Kirschbaum11*, Regina Reim11*, Ulrike Sutter11*, Katrin Vetter11*, Hartmut Döhner, MD11*, Richard F. Schlenk, MD12 and Konstanze Döhner, MD11

1Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
2Hematology and Oncology Practice, Augsburg, Germany
3Otto-von-Guericke University Medical Center Magdeburg, Magdeburg, Germany
4Department of Hematology/Oncology, Klinikum Minden, Minden, Germany
5Department of Internal Medicine, Stauferklinikum Schwäbisch Gmünd, Mutlangen, Germany
6Department of Haematology and Medical Oncology, Department of Internal Medicine II, University Hospital Jena, Jena, Germany
7Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, RWTH Aachen University Hospital, Aachen, Germany
8Department of Hematology and Oncology, University Tübingen, Tübingen, Germany
9Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany
10University of Cologne, Cologne, Germany
11Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
12University Hospital of Ulm, Ulm, Germany

5:30 PM

Simon T Durrant1, Arnon Nagler2*, Alessandro M Vannucchi3*, David Lavie, MD4*, Charles Chuah5, Francesco Passamonti6*, Heinz Gisslinger, MD7, Philipp le Coutre8*, Prashanth Gopalakrishna, MBBS, MRCS9*, Bruyère Mahuzier10*, Shuyuan Mo11* and Joaquin Martinez-Lopez12*

1Royal Brisbane Hospital, Herston, Australia
2The Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
3University of Florence, Florence, Italy
4Department of Hematology and Bone Marrow Transplantation, Hebrew University-Hadassah Medical Organization, Jerusalem, Israel
5Department of Hematology, Singapore General Hospital, Singapore, Singapore
6Ospedale di Circolo e Fondazione Macchi, Varese, Italy
7Medical University of Vienna, Vienna, Austria
8Schumannstr, Medizinische Klinik m. S. Hämatologie und Onkologi, Berlin, Germany
9Novartis Pharma AG, Basel, Switzerland
10Novartis Pharma S.A.S, Rueil-Malmaison, France
11Novartis Pharmaceuticals Corporation, East Hanover, NJ
12Hospital-12-de-Octubre, Madrid, Spain

5:45 PM

Animesh Pardanani, MBBS, PhD1, Terra L. Lasho, PhD2*, Christy Finke, BS2*, Darci Zblewski, CNP2*, Ramy Abdelrahman, M.B., B.Ch.2*, Emnet Wassie, M.D.2*, Naseema Gangat, MBBS2, Curtis A. Hanson, MD3, Rhett P. Ketterling, MD4* and Ayalew Tefferi, MD2

1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
2Division of Hematology, Mayo Clinic, Rochester, MN
3Division of Hematopathology, Mayo Clinic, Rochester, MN
4Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

*signifies non-member of ASH